Mayıs ayında Seth Klarman'ı Vaxcyte'e kadar takip ettiyseniz, çoktan gitmişti

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Omor Ibne Ehsan

Sun, August 16, 2026 at 10:45 PM GMT+3 4 min read

• PCVX -1.34%
• WTW -0.72%

Quick Read

• Baupost dumped all 800,000 PCVX shares and 893,126 WTW shares by June 30, weeks before retail investors learned Klarman had held either.

• 13F filings run 45 days stale, so retail investors who copied Klarman's disclosed PCVX stake bought a position he had already abandoned.

• Vaxcyte's OPUS-1 Phase 3 readout arrives Q4 2026, but a $284 million Q2 loss and $602 million equity raise sharpened Baupost's exit logic.

• The most widely read finance newsletter on Substack isn't published by a bank, it's Doomberg, where 383,000+ readers get the energy and macro analysis the mainstream press misses. 24/7 Wall St. readers save 17% on their first year here.

Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX) during the June quarter, according to the 13F filed August 13, 2026. The position went from 800,000 shares to zero, a reduction of 800,000 shares and a change in position value of -$46,488,000. In the same filing, Baupost also exited Willis Towers Watson (NASDAQ:WTW), reducing its position from 893,126 shares to zero, a -100% change with a position value change of -$259,632,000. Both were positions Baupost had only recently established.

The prior 13F, covering holdings as of March 31, 2026, was filed in mid-May, revealing a fresh Vaxcyte stake. Retail investors who took that as a Klarman endorsement and bought alongside him were stepping into a position that Baupost would eliminate entirely by June 30. The May stock price at the Q1 earnings filing was $56.00. By the time anyone knew Klarman had walked away, the quarter he walked away in was already six weeks over.

From Our Partners

Written by Insiders. Answering to No One.

Before Doomberg published a word, its team spent long careers in heavy industry, private equity, and the hard sciences. They take no advertisers and serve no institution — which is why their lateral-thinking coverage of energy, finance, and geopolitics reads nothing like consensus financial media. Doomberg has set aside a discounted rate exclusively for 24/7 Wall St. readers — it isn't available on their main page.

Claim the 24/7 Wall St. Rate →

What the Thesis Likely Was, and Why It Broke

Vaxcyte is a clinical-stage vaccine developer with no product revenue. Its value hinges on VAX-31, a 31-valent pneumococcal conjugate vaccine being run head-to-head against competing pneumococcal vaccines in the OPUS-1 Phase 3 trial, with topline data expected in the fourth quarter of 2026. That is a binary event on a defined timeline, and value investors sometimes take pre-catalyst positions when they think the market misprices probability. It is a legitimate trade, but it is also the kind Baupost historically closes fast if the risk/reward tightens.

The financial profile makes the exit easier to rationalize. Vaxcyte reported a Q2 2026 net loss of $284.30 million on $267.85 million in R&D spending, and it leaned on a $601.80 million equity offering in February 2026 to keep the runway wide. The cash pile of $2.51 billion is real, but so is the dilution reflex any time the stock rallies into a catalyst.

WTW, by contrast, is profitable, buying back stock aggressively, and posted adjusted diluted EPS of $3.35 on $2.47 billion in revenue in Q2 2026, with a Propel AI plan targeting roughly 30% adjusted operating margin by 2028. Klarman exited anyway. That suggests the trade was opportunistic rather than a long-term conviction hold.

What This Means for a Retail Investor

A 13F is a photograph of a date already about forty-five days in the past. The May disclosure reflected only what Baupost owned on March 31, giving no visibility into subsequent positioning through May or the June exit. Following a fund into a pre-catalyst biotech based on a two-month-old snapshot is copying the setup while missing the exit.

Use 13Fs to generate ideas and to understand how sophisticated allocators size risk, then underwrite the position yourself against the actual catalyst calendar. For Vaxcyte, that calendar runs through OPUS-1 in Q4 2026 and OPUS-2 and OPUS-3 in H1 2027. Owning the thesis means being willing to sit through those readouts. Klarman was not, and his disclosure will not tell you when he changes his mind again.

What $28 a Month Buys a Serious Investor

Through this reader link, 24/7 Wall St. readers get their first year of Doomberg for $332 — 17% off the standard $400, which works out to about $28 a month. That buys six to eight deeply researched articles a month on energy, finance, and geopolitics, the full archive, and one of the most resource-rich comment sections anywhere, where engineers, executives, and fund managers add context under every piece. After the first year it renews at the standard rate, and you can cancel anytime. If today's article touched energy or the macro picture, odds are the green chicken has already gone three layers deeper — see for yourself at the discounted rate.

Contact editorial@247wallst.com for any questions or corrections.